GSK PLC-SPON ADR (GSK) Stock Price, Forecast & Analysis
NYSE:GSK • US37733W2044
GSK Key Statistics, Chart & Performance
The current stock price of GSK is 59.52 USD. In the past month the price increased by 22.34%. In the past year, price increased by 62.45%.
GSK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GSK. When comparing the yearly performance of all stocks, GSK is one of the better performing stocks in the market, outperforming 90.19% of all stocks.
GSK Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GSK. While GSK belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
GSK Financial Highlights
Over the last trailing twelve months GSK reported a non-GAAP Earnings per Share(EPS) of 4.71. The EPS increased by 7.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.5% | ||
| ROA | 9.35% | ||
| ROE | 34.9% | ||
| Debt/Equity | 0.9 |
GSK Forecast & Estimates
32 analysts have analysed GSK and the average price target is 51.62 USD. This implies a price decrease of -13.28% is expected in the next year compared to the current price of 59.52.
For the next year, analysts expect an EPS growth of 8.81% and a revenue growth 5.1% for GSK
GSK Ownership
GSK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.08 | 967.332B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 594.88B | ||
| MRK | MERCK & CO. INC. | 22.6 | 302.459B | ||
| PFE | PFIZER INC | 8.87 | 152.718B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 122.756B | ||
| ZTS | ZOETIS INC | 18.75 | 56.091B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.039B | ||
| VTRS | VIATRIS INC | 6.29 | 18.405B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.89 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.33 | 9.385B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GSK
Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Company Info
GSK PLC-SPON ADR
980 Great West Road
Brentford MIDDLESEX TW8 9GS GB
CEO: Emma Walmsley
Employees: 68629
Phone: 442080475000
GSK PLC-SPON ADR / GSK FAQ
Can you describe the business of GSK PLC-SPON ADR?
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
What is the stock price of GSK PLC-SPON ADR today?
The current stock price of GSK is 59.52 USD. The price decreased by -2.19% in the last trading session.
Does GSK PLC-SPON ADR pay dividends?
GSK PLC-SPON ADR (GSK) has a dividend yield of 3.27%. The yearly dividend amount is currently 1.65.
What is the ChartMill technical and fundamental rating of GSK stock?
GSK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for GSK stock?
The PE ratio for GSK PLC-SPON ADR (GSK) is 12.64. This is based on the reported non-GAAP earnings per share of 4.71 and the current share price of 59.52 USD.
How many employees does GSK PLC-SPON ADR have?
GSK PLC-SPON ADR (GSK) currently has 68629 employees.
What is GSK PLC-SPON ADR worth?
GSK PLC-SPON ADR (GSK) has a market capitalization of 119.44B USD. This makes GSK a Large Cap stock.